Comprehensive interpretation of the indications and applicable groups of ritexitinib (Lefenox)

Ritlecitinib is an oral JAK3/TEC kinase inhibitor mainly used for targeted therapy of immune-related diseases. Its mechanism of action regulates abnormal immune system responses by inhibiting the JAK-STAT signaling pathway and TEC family kinases, thereby reducing inflammatory responses and autoimmune attacks. This property makes ritexitinib show potential in the treatment of autoimmune diseases and hair loss diseases, providing patients with new treatment options.

Currently, ritexitinib is mainly approved for the treatment of alopecia areata (AA), especially in patients with moderate to severe alopecia areata. Its efficacy has been proven in multiple clinical trials and can significantly improve hair regeneration, and is also effective for patients with eyebrow, eyelash and other body hair loss. In addition, ritexitinib also has potential applications in exploring the treatment of other autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), etc. However, the current main clinical application is still in hair loss diseases.

Rituxitinib is indicated for adults and adolescents with moderate to severe alopecia areata, especially those who have failed to respond to conventional topical corticosteroids or immunosuppressive treatments. For patients with a long course of disease, extensive hair loss, or accompanied by body hair loss, ritexitinib can be used as the first or second-line treatment option. In addition, patients must have no contraindications such as severe infection, active tuberculosis, or severe abnormalities in liver and kidney function to ensure the safety of the medication.
When using ritexitinib, doctors should develop an individualized medication plan based on the patient's degree of hair loss, course of disease, and previous treatment history. During the treatment process, blood routine, liver and kidney function and immune indicators need to be monitored regularly to evaluate the efficacy and adverse reactions. For patients with obvious curative effect, the recommended dose can be maintained to continue treatment; if mild to moderate side effects occur, the dose can be adjusted or the medication can be used intermittently under the guidance of a doctor. Through scientific management and individualized regimens, ritexitinib can provide a long-term and safe treatment option for patients with moderate to severe alopecia areata.
Reference: https://www.drugs.com/